Clinical data | |
---|---|
Pregnancy category |
|
Routes of administration | oral |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 100% (oral) |
Metabolism | hepatic |
Elimination half-life | 9–13 hours |
Excretion | 76% renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C20H28N2O5S |
Molar mass | 408.51 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Tamsulosin (rINN) (Template:PronEng) is an α1a-selective alpha blocker used in the symptomatic treatment of benign prostatic hyperplasia (BPH). Tamsulosin was developed by Yamanouchi Pharmaceuticals (now part of Astellas Pharma) and is marketed by various companies under licence, including Boehringer-Ingelheim and CSL. As of 2006, tamsulosin hydrochloride extended-release tablets are marketed under the trade name Flomaxtra. It was formerly marketed as modified-release capsules under the trade name Flomax.
Two ADRs (Adverse Drug Reactions) have been reported:
Tamsulosin has also affected the sexual function in men. Tamsulosin can cause males to experience retrograde ejaculation.
Although prostate specific, it does not have the prostate apoptotic effects of other alpha-blockers such as doxazosin and terazosin.